[Does liraglutide have a place in psychiatry ?].

Rev Med Suisse

Unité de pharmacogénétique et de psychopharmacologie clinique, Centre de neurosciences psychiatriques, Département de psychiatrie, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.

Published: March 2022

The relative risk of developing MetS is higher in patients with severe mental illness (SMI) than in the general population. Similarly, the risk of developing obesity or type 2 diabetes (T2DM) is also higher in patients with SMI. GLP-1 receptor agonists, such as liraglutide, have been shown to be effective in the treatment of T2DM and, more recently, in obesity or overweight associated with at least one metabolic disease. Their psychiatric adverse effect profiles seem to be reassuring, thus not represent a limitation for prescribing in psy chiatry. We aimed to explore the therapeutic usefulness of liraglutide in patients with psychiatric disorders associated with somatic comorbidities such as obesity, T2DM or MetS.

Download full-text PDF

Source
http://dx.doi.org/10.53738/REVMED.2022.18.774.522DOI Listing

Publication Analysis

Top Keywords

risk developing
8
higher patients
8
[does liraglutide
4
liraglutide place
4
place psychiatry
4
psychiatry relative
4
relative risk
4
developing mets
4
mets higher
4
patients severe
4

Similar Publications

Burns carry a large surface area, varying in shapes and depths, and an elevated risk of infection. Regardless of the underlying etiology, burns pose significant medical challenges and a high mortality rate. Given the limitations of current therapies, tissue-engineering-based treatments for burns are inevitable.

View Article and Find Full Text PDF

Lupus disease activity state and Foxp3 gene polymorphism.

Egypt J Immunol

January 2025

Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

The autoimmune disease systemic lupus erythematosus (SLE) is presented with many clinical symptoms. The transcription factor fork head box protein 3 (Foxp3) is expressed on regulatory T (T-reg) cells and essential for its development and function. Functional single-nucleotide polymorphisms (SNPs) in the Foxp3-3279 (rs3761548 C/A) gene influence SLE pathogenesis.

View Article and Find Full Text PDF

Anti-Amyloid Therapies for Alzheimer's Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician.

Ann Emerg Med

January 2025

Departments of Emergency Medicine & Population Health, New York University Grossman School of Medicine, New York, NY; Geriatric Research, Education and Clinical Center, James J. Peters Veterans Affairs Medical Center, Bronx, NY.

Alzheimer's disease is the neurodegenerative disorder responsible for approximately 60% to 70% of all cases of dementia and is expected to affect 152 million by 2050. Recently, anti-amyloid therapies have been developed and approved by the Food and Drug Administration as disease-modifying treatments given as infusions every 2 to 5 weeks for Alzheimer's disease. Although this is an important milestone in mitigating Alzheimer's disease progression, it is critical for emergency medicine clinicians to understand what anti-amyloid therapies are and how they work to recognize, treat, and mitigate their adverse effects.

View Article and Find Full Text PDF

Risk and Protective Factors for the Evolution of Subthreshold Depression During Early Adolescence.

J Adolesc Health

January 2025

Laboratory of Cognitive Control and Brain Healthy, Department of Psychology, School of Public Health, Southern Medical University, Guangzhou, China; Department of Psychiatry, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Electronic address:

Purpose: Subthreshold depression refers to a condition involving clinically significant depressive symptoms that fall short of meeting the diagnostic criteria for major depressive disorder (MDD). Identifying risk and protective factors associated with the progression of subthreshold depression in early life is essential for timely prevention. However, there is limited research on this topic among early adolescents.

View Article and Find Full Text PDF

A conceptual framework for identifying and managing system vulnerabilities for diversion of controlled substances in healthcare.

Res Social Adm Pharm

January 2025

Institute of Health Policy, Management and Evaluation, University of Toronto, 155 College Street, Suite 425, Toronto, Ontario, M5T 3M6, Canada; Research & Innovation, North York General Hospital, 4001 Leslie Street, Toronto, Ontario, M2K 1E1, Canada.

Purpose: Diversion or theft of controlled substances is a recognized problem affecting healthcare systems globally. The purpose of this study was to develop a framework for identifying and characterizing system factors leading to vulnerabilities for diversion within hospitals.

Methods: We applied a qualitative framework method, which involved 1) compiling a list of critical diversion vulnerabilities through observations and proactive risk analyses in the inpatient pharmacy, emergency department and intensive care unit of two Canadian hospitals; 2) coding the vulnerabilities into deductively and inductively derived themes and subthemes; and 3) building a conceptual framework.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!